CONFERENCE COVERAGE SERIES
Kloster Seeon meeting on BACE proteases in health and disease
Seeon-Seebruck, Bavaria, Germany
25 – 27 September 2016
Since the first Kloster Seeon meeting on β-secretases in 2013, a handful of BACE inhibitors have entered clinical trials and researchers have learned more about what these proteases do in development and adulthood. What’s the status of the field in the fall of 2016? Check out our coverage of the 2nd Kloster Seeon meeting. Highlights include conditional BACE1 knockouts, updates on non-APP substrates cleaved by BACE, news about BACE’s role in dystrophic neurites, assays to measure off-target effects and—finally—the arrival of BACE1-selective inhibitors.
At 2nd Kloster Seeon Meeting, Renewed Optimism for Targeting BACE1
Despite concerns over potential side effects, researchers seem more enthusiastic than ever about the prospect of treating Alzheimer’s with β-secretase inhibitors.
What Exactly Does BACE Do in Adults?
Researchers at the Kloster Seeon meeting pressed in on the question of what are the physiological functions of this protease after development is complete.
BACE Inhibition and the Synapse—Insights from Seeon
At the 2nd Kloster Seeon meeting on BACE proteases, researchers linked BACE substrates to regulation of synaptic activity.
Does BACE Drive Neurites into Dystrophy, Shorting Circuits?
In Seeon, researchers reported that blocking the protease may heal dystrophic neurites and repair electrical activity.
Will Next-Gen BACE Inhibitors Dodge Side Effects?
Despite no warning signs in ongoing clinical trials, researchers are searching for safer drugs, and better biomarkers to measure what they do.